NPPA and neurodevelopmental disorder: Future studies employing other genetically modified mouse strains designed to ADHD and/or ASD model are needed to evaluate whether changes in KP metabolites can be used as a clinical biomarker for improving specificity when diagnosing neurodevelopmental disorders.